This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is closed. The potential of Raloxifene (Evista ) to improve the cognition and skills of independent living is being investigated with a 3-month intervention study, enrolling women with Alzheimer's Disease (AD). Subjects are asked to take 120 mg/day raloxifene or a matching placebo pill. They are asked to undergo cognitive testing and an assessment of skills of independent living throughout the study while taking the investigational medication, and then again 2 months after ending treatment. Cognitive performance while on medication will be compared to a baseline pre-treatment testing session.
Showing the most recent 10 out of 459 publications